Journal
NATURE MEDICINE
Volume 10, Issue 4, Pages 363-364Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm1004
Keywords
-
Funding
- NIDDK NIH HHS [DK44863] Funding Source: Medline
Ask authors/readers for more resources
Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2(-/tm1Som)), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available